Join hands with Xue Dingping, a global leader in AI drug design! Xiansheng Pharmaceutical (02096) relies on “physics+AI” dual technology to reshape the valuation logic of innovative drug pipelines

The Zhitong Finance App learned that on July 10, 2026, Xiansheng Pharmaceutical (02096) announced that it had recently reached a global drug discovery and development cooperation agreement with Schrödinger of the United States. The two sides will give full play to their respective advantages in drug research and development, focus on unmet clinical needs, and jointly promote innovative drug research and development, relying on Xiansheng Pharmaceutical's expertise in related treatment fields.

Zhou Gaobo, Chief Investment Officer of Xiansheng Pharmaceutical, said, “We are very pleased to have reached a strategic partnership with Schrödinger, a global leader in computational drug discovery. The two sides will deeply integrate Schrödinger's world-leading drug design expertise based on physics and artificial intelligence, as well as Xiansheng Pharmaceuticals' efficient R&D capabilities and commercialization platforms. We look forward to accelerating the discovery, development and commercialization of cutting-edge therapies through complementary strengths and collaborative innovation to provide more groundbreaking treatment solutions for patients around the world.”

Karen Akinsanya, President of Schrödinger, Head of Therapeutics Research and Development, and Chief Strategic Cooperation Officer, said, “We are delighted to launch this strategic partnership with Xiansheng Pharmaceuticals to jointly develop innovative drugs that meet critical clinical needs. This collaboration continues our successful model of discovering innovative clinical drug candidates on high-value targets. By combining our leading edge in 'predictive priority' differentiated drug design with Xiansheng Pharmaceutical's outstanding capabilities in innovative R&D and clinical development execution in China, we look forward to accelerating the development process of innovative therapeutics and bringing more treatment options to patients around the world.”

With its leading physics-driven computing platform and expertise, Schrödinger will be responsible for computer-aided drug design and optimization in the joint drug discovery phase. After the combined drug discovery phase is completed, Xiansheng Pharmaceutical will lead subsequent pre-clinical research and clinical development. Under the agreement, Schrödinger is entitled to receive milestone payments for cooperative projects in the discovery, development and commercialization stages, as well as tiered royalties based on net product sales.